Licensing Trial Drugs To Foreign Firms A Failure For Indian Pharmas
This article was originally published in PharmAsia News
The practice of Indian drug makers of licensing to foreign companies some of the molecules they have in clinical trials has not been a successful one for the licensing firms. Many of the licensed molecules have failed to survive late-stage trials, with a result of the foreign licensees simply abandoning them. Facing a shortage of finances necessary to carry on the work themselves, major Indian pharmas today focus on secondary research activities such as new delivery systems. (Click here for more
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
With Roche's oral spinal muscular atrophy therapy Evrysdi off to a strong start after its recent US launch, Novartis is switching its priorities for rival RNA-splicing drug branaplam and putting it into a Phase IIb trial for Huntington's disease.
Nuvation started in 2018 and raised a $275m series A round in 2019. Now it is merging with the EcoR1 Capital-sponsored SPAC Panacea Acquisition Corp. and raising $500m in equity capital.